216 related articles for article (PubMed ID: 30745395)
1.
Bleasby K; Fillgrove KL; Houle R; Lu B; Palamanda J; Newton DJ; Lin M; Chan GH; Sanchez RI
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745395
[TBL] [Abstract][Full Text] [Related]
2. Islatravir Is Not Expected to Be a Victim or Perpetrator of Drug-Drug Interactions via Major Drug-Metabolizing Enzymes or Transporters.
Bleasby K; Houle R; Hafey M; Lin M; Guo J; Lu B; Sanchez RI; Fillgrove KL
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452431
[TBL] [Abstract][Full Text] [Related]
3. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
[TBL] [Abstract][Full Text] [Related]
4. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.
Chu X; Cai X; Cui D; Tang C; Ghosal A; Chan G; Green MD; Kuo Y; Liang Y; Maciolek CM; Palamanda J; Evers R; Prueksaritanont T
Drug Metab Dispos; 2013 Mar; 41(3):668-81. PubMed ID: 23293300
[TBL] [Abstract][Full Text] [Related]
5. In vitro cytochrome P450- and transporter-mediated drug interaction potential of 6β-hydroxy-21-desacetyl deflazacort-A major human metabolite of deflazacort.
Ma J; Beers B; Manohar R; Roe S; Colacino JM; Kong R
Pharmacol Res Perspect; 2021 Apr; 9(2):e00748. PubMed ID: 33749127
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1.
Kimoto E; Vourvahis M; Scialis RJ; Eng H; Rodrigues AD; Varma MVS
Drug Metab Dispos; 2019 May; 47(5):493-503. PubMed ID: 30862625
[TBL] [Abstract][Full Text] [Related]
7. Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.
Rizk ML; Houle R; Chan GH; Hafey M; Rhee EG; Chu X
Antimicrob Agents Chemother; 2014; 58(3):1294-301. PubMed ID: 24295974
[TBL] [Abstract][Full Text] [Related]
8. The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug-Drug Interactions in a Clinical Setting-Proposal of a Four Component Transporter Cocktail.
Ebner T; Ishiguro N; Taub ME
J Pharm Sci; 2015 Sep; 104(9):3220-8. PubMed ID: 25981193
[TBL] [Abstract][Full Text] [Related]
9. In Vitro Interactions of Epacadostat and its Major Metabolites with Human Efflux and Uptake Transporters: Implications for Pharmacokinetics and Drug Interactions.
Zhang Q; Zhang Y; Boer J; Shi JG; Hu P; Diamond S; Yeleswaram S
Drug Metab Dispos; 2017 Jun; 45(6):612-623. PubMed ID: 28283500
[TBL] [Abstract][Full Text] [Related]
10. Identification of Transporters Involved in Beraprost Sodium Transport In Vitro.
Oshida K; Shimamura M; Seya K; Ando A; Miyamoto Y
Eur J Drug Metab Pharmacokinet; 2017 Feb; 42(1):117-128. PubMed ID: 26961540
[TBL] [Abstract][Full Text] [Related]
11. In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
Chino Y; Hasegawa M; Fukasawa Y; Mano Y; Bando K; Miyata A; Nakai Y; Endo H; Yamaguchi JI
Xenobiotica; 2017 Apr; 47(4):314-323. PubMed ID: 27324291
[TBL] [Abstract][Full Text] [Related]
12. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
Zurth C; Koskinen M; Fricke R; Prien O; Korjamo T; Graudenz K; Denner K; Bairlein M; von Bühler CJ; Wilkinson G; Gieschen H
Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):747-759. PubMed ID: 31571146
[TBL] [Abstract][Full Text] [Related]
13. Preclinical assessment of drug-drug interaction of fb-PMT, a novel anti-cancer thyrointegrin αvβ3 antagonist.
Fujioka K; Fekry MI; Rumsey JM; Steiner T; Thompson D; Mousa SA
Clin Transl Sci; 2023 Jun; 16(6):987-1001. PubMed ID: 36967488
[TBL] [Abstract][Full Text] [Related]
14. In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor.
Zhang H; Ou YC; Su D; Wang F; Wang L; Sahasranaman S; Tang Z
Pharmacol Res Perspect; 2021 Dec; 9(6):e00870. PubMed ID: 34664792
[TBL] [Abstract][Full Text] [Related]
15. Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam.
Reese MJ; Bowers GD; Humphreys JE; Gould EP; Ford SL; Webster LO; Polli JW
Xenobiotica; 2016; 46(5):445-56. PubMed ID: 26340566
[TBL] [Abstract][Full Text] [Related]
16. An Assessment of the In Vitro Inhibition of Cytochrome P450 Enzymes, UDP-Glucuronosyltransferases, and Transporters by Phosphodiester- or Phosphorothioate-Linked Oligonucleotides.
Kazmi F; Yerino P; McCoy C; Parkinson A; Buckley DB; Ogilvie BW
Drug Metab Dispos; 2018 Aug; 46(8):1066-1074. PubMed ID: 29735754
[TBL] [Abstract][Full Text] [Related]
17. Organic anion transporter 3- and organic anion transporting polypeptides 1B1- and 1B3-mediated transport of catalposide.
Jeong HU; Kwon M; Lee Y; Yoo JS; Shin DH; Song IS; Lee HS
Drug Des Devel Ther; 2015; 9():643-53. PubMed ID: 25653502
[TBL] [Abstract][Full Text] [Related]
18. In Vitro Interaction of AB-FUBINACA with Human Cytochrome P450, UDP-Glucuronosyltransferase Enzymes and Drug Transporters.
Kim S; Kim DK; Shin Y; Jeon JH; Song IS; Lee HS
Molecules; 2020 Oct; 25(19):. PubMed ID: 33050066
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of
Liao M; Jaw-Tsai S; Beltman J; Simmons AD; Harding TC; Xiao JJ
Xenobiotica; 2020 Sep; 50(9):1032-1042. PubMed ID: 32129697
[TBL] [Abstract][Full Text] [Related]
20. Rhinacanthin-C Mediated Herb-Drug Interactions with Drug Transporters and Phase I Drug-Metabolizing Enzymes.
Dunkoksung W; Vardhanabhuti N; Siripong P; Jianmongkol S
Drug Metab Dispos; 2019 Oct; 47(10):1040-1049. PubMed ID: 31399508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]